Oruka Therapeutics, Inc. Operating Lease, Expense
Oruka Therapeutics, Inc. (ORKA) reported Operating Lease, Expense of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-10
- Oruka Therapeutics, Inc. operating lease, expense for the quarter ending 2026-06-30 was $200.00K, a 33.33% decline year-over-year.
- Oruka Therapeutics, Inc. operating lease, expense for the quarter ending 2026-03-31 was $200.00K, a 100.00% increase year-over-year.
- Oruka Therapeutics, Inc. operating lease, expense for the quarter ending 2025-06-30 was $300.00K.
- Oruka Therapeutics, Inc. operating lease, expense for the quarter ending 2025-03-31 was $100.00K.
- Oruka Therapeutics, Inc. operating lease, expense for fiscal 2025 was $900.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 8 month | Operating Lease, Expense 11 month | Operating Lease, Expense 11 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-10 | $500.00K 10-Q · filed 2026-08-10 | |||||
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-13 | ||||||
| 2025-12-31 | $900.00K 10-K · filed 2026-03-12 | ||||||
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-10 | $400.00K 10-Q · filed 2026-08-10 | |||||
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-13 | $62.00K 10-Q · filed 2025-05-14 | |||||
| 2024-12-31 | $300.00K 10-K · filed 2026-03-12 | $127.00K 10-K · filed 2025-03-06 | |||||
| 2024-09-30 | $65.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |